Effect of Cerefolin®/CerefolinNAC® on Biomarker Measurements

Completed

Conditions studied: Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease Related Disorders

In brief

In a retrospective analysis of data from 1100 patients, disease-delaying effects of Cerefolin®/CerefolinNAC® were examined in terms of cognition. The purpose of the current study is to expand the retrospective study dataset by prospectively collecting additional biomarker and imaging data.

Key facts

Study ID

NCT01745198

Run by

Pamlab, Inc.

People needed

121

Starts

2012-12-01

Expected to finish

2014-06-01

Last updated by the study team

2015-04-28

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• With a diagnosis of normal aging (NL), cognitive impairment or dementia not otherwise specified (CI/D), or ADRD
• With at least one previous quantitative MRI (qMRI)
• With at least one previous homocysteine level
• Without homocysteinemia plus no past or current B12, folate or Cerefolin® treatment, OR with homocysteinemia plus past or current Cerefolin® treatment

You may not qualify if…

• Subjects who do not meet the inclusion criteria will be excluded from the study.

Where it is running

• Hoag Memorial Hospital — Newport Beach, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.